[1]Moreau P., Mateos M.V., Berenson J.R. Once weekly twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19:953-964. versus
[2]Moreau P., Kumar S., Boccia R. Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m 2 twice-weekly 27 mg/m 2 carfilzomib (randomized A.R.R.O.W. study). Leukemia. 2019;33:2934-2946. vs.